Stephen Apple - Mitsubishi Tanabe Pharma Amer

基本信息

浏览量：5

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 46 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Safety Extension Study of Edaravone Oral Suspension in Patients with Amyotrophic Lateral Sclerosis for Up to an Additional 96 Weeks of Treatment

Angela Genge, Gary L Pattee,Gen Sobue,Masashi Aoki,Hiide Yoshino, Philippe Couratier,Christian Lunetta,Susanne Petri,Daniel Selness, Vesna Todorovic, Nissim Sasson, Manabu Hirai,Fumihiro Takahashi,Alejandro Salah,Stephen Apple,Art Wamil, Alexander Kalin, Carlayne E Jackson

Muscle & nerve (2025)

引用0浏览0WOS引用

Efficacy and Safety of Once Daily Dosing Vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients with Amyotrophic Lateral Sclerosis (study MT-1186-A02)

Jeffrey Rothstein,Angela Genge, Shari De Silva,Lorne Zinman,Marvin Chum,Adriano Chio,Gen Sobue,Masashi Aoki,Hiide Yoshino,Manabu Doyu,Daniel Selness, Vesna Todorovic, Nissim Sasson, Manabu Hirai,Fumihiro Takahashi,Alejandro Salah,Art Wamil,Stephen Apple

Muscle & nerve (2025)

引用0浏览0WOS引用

Efficacy of Radicava® IV (intravenous Edaravone) in Subjects with Differing Trajectories of Disease Progression in Amyotrophic Lateral Sclerosis: Use of a Novel Statistical Approach for Post Hoc Analysis of a Pivotal Phase 3 Clinical Trial

Erik P. Pioro,Benjamin Rix Brooks, Ying Liu,Jeffrey Zhang,Stephen Apple

JOURNAL OF THE NEUROLOGICAL SCIENCES（2024）

引用0浏览0WOS引用

PHASE 3B STUDY MT-1186-A02 TO INVESTIGATE THE SUPERIORITY OF DAILY DOSING VS THE FDA-APPROVED ON/OFF REGIMEN OF ORAL EDARAVONE IN PATIENTS WITH AMYOTROPHIC LATER SCLEROSIS

Jeffrey Rothstein,Angela Genge, Shari De Silva,Lorne Zinman,Marvin Chum,Adriano Chio,Gen Sobue,Manabu Doyu,Daniel Selness,Vesna Todorovic, Nissim Sasson,Fumihiro Takahashi,Alejandro Salah,Art Wamil,Stephen Apple

MUSCLE & NERVEno. 3 (2024): 512-512

引用0浏览0引用

Phase 3, Open-Label, Safety Extension Study of Oral Edaravone Administered over 96 Weeks in Patients with ALS (MT-1186-A03)

Angela Genge,Gary Pattee,Gen Sobue,Masashi Aoki,Hiide Yoshino,Philippe Couratier,Christian Lunetta,Susanne Petri,Vesna Todorovic,Manabu Hirai,Alejandro Salah,Stephen Apple,Art Wamil,Alexander Kalin,Carlayne Jackson

MUSCLE & NERVEno. 3 (2024): 513-513

引用0浏览0引用

The Effects of Intervention with Intravenous Edaravone in Study 19 on Hospitalization, Tracheostomy, Ventilation, and Death in Patients with Amyotrophic Lateral Sclerosis

Benjamin Rix Brooks,Erik P. Pioro,Takeshi Sakata,Fumihiro Takahashi,Melissa Hagan,Stephen Apple

Muscle & Nerveno. 4 (2023): 397-403

引用0浏览0WOS引用

Real-World Evidence on Treatment Patterns, Clinical Outcomes, and Patient-Reported Outcomes of Intravenous Edaravone-Treated People With Amyotrophic Lateral Sclerosis in the ALS/MND Natural History Consortium Registry Database

Alexander V. Sherman,Jeffrey Zhang, Ying Liu,Alex Berger,Matteo Locatelli, Kinjal Patel,Malgorzata Ciepielewska,Stephen Apple

MUSCLE & NERVE（2023）

引用0浏览0引用

Phase 3B Study Evaluating Superiority of Daily Dosing Vs Approved On/off Oral Edaravone Dosing over 48 Weeks in Patients with Amyotrophic Lateral Sclerosis (MT-1186-A02)

Alejandro Salah,Shari Desilva,Lorne Zinman,Marvin Chum,Adriano Chio,Albert C. Ludolph,Gen Sobue,Manabu Doyu,Daniel Selness,Vesna Todorovic,Manabu Hirai,Art Wamil,Stephen Apple

Journal of the Neurological Sciences（2023）

引用0浏览0引用

Phase 3, Open-Label, Multicenter Safety Study of Oral Edaravone in Patients with Amyotrophic Lateral Sclerosis (MT1186-A01): 48-Week Results

Angela Genge,Gary L. Pattee,Gen Sobue,Philippe Couratier,Daniel Selness,Sachin Bidani,Manabu Hirai,Alejandro Salah,Stephen Apple

Journal of the Neurological Sciences（2023）

引用0浏览0引用

Real-world Evidence on Treatment Retention, Safety, and Tolerability of Edaravone in Canadian Patients with Amyotrophic Lateral Sclerosis (P5-11.012)

Dung Pham, Louise St-Onge, Ryan Ng,Calum S. Neish, Belinda Yap,Stephen Apple

MUSCLE & NERVE（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn